Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
"confident that the steps we have taken in the last few months are consistent with a completion date during 2023"
So another 16 months potentially as not even a Q mentioned, so Q4 a possibility. Dreadful news: to bail out or not to bail, I ask myself?
Although Angle will make money from selling the Parsortix widget, there may be more money in collaboration or developing in house downstream anayses. "Once developed, the new assays will remain in the ownership of ANGLE and be added to ANGLE's menu of pre-developed tests that can be offered to other pharma customers" There is a lot more money to be made in collaboration with big pharma. Happy days are just around the corner..
Daz
Evidence light statements.
Compoundinterest
Do you mean something other than sens/spec, which does not seem to apply to Parsortix? Are you asking if, in the presence of a known tumour (say breast), what are the chances of isolating CTCs from peripheral blood ? Answer i don't know! And there may be a different answer for isolating (dormant) tumour cells from bone marrow, which is a promising avenue of research. The problem for cancer treatment seems to lie in the way tumour cells mutate over time, so that gene expression of a tumour cell may differ and with it, the treatment options. This is where Parsortix is so powerful at making possible downstream examination of the changes of gene expression over time.
VLS very much swimming against the tide today.
Malik
So I read it. Some of the figures are crazy and perhaps the product of someones imagination, or sloppy writing.
"ACME Group is investing $2.5bn to set up a large-scale hydrogen facility capable of producing 2,200 million tonnes of green ammonia per day in Duqm, Oman." Should be enough for starters!
NutHazard
What is the relationship, if any, between PowerhouseAfrica ( and PowerHouse America) and PHE here in UK? I have a vague memory of PHE, when being developed in Australia, having an offshoot in the USA, but that was years back. Powerhouse Africa seems to be using the Pyromex system - an old name for what is now DMG - for all types of waste. My assumption is that two quite distinct firms are using the same name.
Yuyus
It does not follow that if someone has a malignancy that there will be CTCs circulating. Take prostate as an example. The malignancy may remain within the prostatic capsule, and there will be no CTCs, nor for that matter, an elevated PSA. Malignant cells break down as do all cells, by apoptosis, and some of the DNA from that dead cell may end up in the circulation where it MIGHT be recognised by Grail - or not. So Grail may or may not be able to recognise the DNA fragment in the blood as coming from prostate, and an ultrasound of the prostate my reveal that there is an intracaspsular tumour. So what would a urologist then do? Watch and wait used to be the the approach, and may still be although I have no up to date knowledge. So at this stage all GRail has done is to crank up needless anxiety.
Screening for undisclosed disease of any sort is a dodgy area. It used to be frightfully fashionable, but the limitation remains, in general, of what to do with the results. And Grail has a mega problem if false positives are as high as quoted. I agree that there is an opportunity to cause massive anxiety for no good reason. The mindset is different in the States, where 'checkups' and repeat office visits are bread and butter to doctors over there. The insurers have a huge responsibility to prevent Grail type screening from getting out of hand, and to stop $$$$$$$ getting into the into the hands of doctors with little or no benefit to the patient.
Parsortix is completely different. It is not a screening tool (except perhaps for foetal abnormalities), and is going to be useful / vital to determine which breathtakinbly expensive cancer treatment should or should not be used.
100 seems a lot - rather more than there are organs in the body - so different cell types from different organs has to make up the difference. But by the time you have covered breast, lung, bowel, (upper and lower), prostate, and skin (melanoma), that covers the great majority of malignancies. Approval for each of these alone will keep Parsortix very busy.
So why the negative response in the SP?
Roland
The word you are looking for is prediction, it has a slightly different meaning from predicament, as in predictive typing, I suppose.
Bermuda
My point was the relatively low CTC capture in what I take to be a disseminated - ie widely metastasising tumour. I accept that it is greatly superior to any other method such as tumour DNA from blood.
But it all counts towards a game changing process for cancer treatment
What surprised me slighly about this paper was that despite brain mets, and presumably spread elsewhere, CTS capture by Parsortix was only 36-50%.
More (un) impressive was the fact that there were 24 authors. This is nonsense; authorship used to be, and should be, much more restricted to those actually providing intellectual input, and writing the paper, and not to any researcher who happened to be in the lab at the time. i digress......
But Angle do not need to produce an RNS for every paper using the Parsortix system any more; they are well past that stage.
I know some of the earlier development work, years ago, was done in Oz, but is there work still going on?
"The material will also support project development work in Australia and Europe." Also the mention of Europe, rather than Poland is interesting; does PHE have developments elsewhere in Europe?